Vivos Therapeutics agrees to debt-to-equity swap with Streeterville Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
June 5, 2026 8:45 AM EDTLITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Vivos or the Company) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to $4.5 million of its outstanding debt into a combination of perpetual, nonconvertible preferred stock and shares of common stock of the Company.
In addition,... More
